Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
aRSjzJvQfSXxagPT
Listen
